Cargando…

High Plus Low Dose Radiation Strategy in Combination with TIGIT and PD1 Blockade to Promote Systemic Antitumor Responses

SIMPLE SUMMARY: This study combines a novel strategy of radiotherapy that utilizes high- and low- dose radiation with immune oncology agents (anti-TIGIT and anti-PD1 monoclonal antibodies) in order to overcome the inhibitory tumor stroma and battle tumors systemically. The findings from this work wi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Barsoumian, Hampartsoum B., Sezen, Duygu, Menon, Hari, Younes, Ahmed I., Hu, Yun, He, Kewen, Puebla-Osorio, Nahum, Wasley, Mark, Hsu, Ethan, Patel, Roshal R., Yang, Liangpeng, Cortez, Maria A., Welsh, James W.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8750272/ https://www.ncbi.nlm.nih.gov/pubmed/35008385 http://dx.doi.org/10.3390/cancers14010221

Ejemplares similares

Addition of TLR9 agonist immunotherapy to radiation improves systemic antitumor activity
por: Younes, Ahmed I., et al.
Publicado: (2020)

Combining a nanoparticle-mediated immunoradiotherapy with dual blockade of LAG3 and TIGIT improves the treatment efficacy in anti-PD1 resistant lung cancer
por: Hu, Yun, et al.
Publicado: (2022)

Pulsed Radiation Therapy to Improve Systemic Control of Metastatic Cancer
por: He, Kewen, et al.
Publicado: (2021)

Pulsed radiotherapy to mitigate high tumor burden and generate immune memory
por: Sezen, Duygu, et al.
Publicado: (2022)

A radioenhancing nanoparticle mediated immunoradiation improves survival and generates long-term antitumor immune memory in an anti-PD1-resistant murine lung cancer model
por: Hu, Yun, et al.
Publicado: (2021)

NLRP3 agonist enhances radiation-induced immune priming and promotes abscopal responses in anti-PD1 resistant model
por: Barsoumian, Hampartsoum B., et al.
Publicado: (2023)

NLRP3 agonist enhances radiation-induced immune priming and promotes abscopal responses in anti-PD1 resistant model
por: Barsoumian, Hampartsoum B., et al.
Publicado: (2023)

Response and outcomes after anti-CTLA4 versus anti-PD1 combined with stereotactic body radiation therapy for metastatic non-small cell lung cancer: retrospective analysis of two single-institution prospective trials
por: Chen, Dawei, et al.
Publicado: (2020)

Bone morphogenetic proteins, activins, and growth and differentiation factors in tumor immunology and immunotherapy resistance
por: Ganjoo, Shonik, et al.
Publicado: (2022)

Novel Use of Low-Dose Radiotherapy to Modulate the Tumor Microenvironment of Liver Metastases
por: He, Kewen, et al.
Publicado: (2021)

Combination treatment with radiotherapy and a novel oxidative phosphorylation inhibitor overcomes PD-1 resistance and enhances antitumor immunity
por: Chen, Dawei, et al.
Publicado: (2020)

Role of Mitochondria in Cancer Immune Evasion and Potential Therapeutic Approaches
por: Klein, Katherine, et al.
Publicado: (2020)

Radiation Therapy Modulates Tumor Physical Characteristics to Reduce Intratumoral Pressure and Enhance Intratumoral Drug Delivery and Retention
por: Barsoumian, Hampartsoum B., et al.
Publicado: (2022)

TIGIT and PD-1 dual checkpoint blockade enhances antitumor immunity and survival in GBM
por: Hung, Alice L., et al.
Publicado: (2018)

Author Correction: Bone morphogenetic protein 7 promotes resistance to immunotherapy
por: Cortez, Maria Angelica, et al.
Publicado: (2020)

Bone morphogenetic protein 7 promotes resistance to immunotherapy
por: Cortez, Maria Angelica, et al.
Publicado: (2020)

Low-dose radiation treatment enhances systemic antitumor immune responses by overcoming the inhibitory stroma
por: Barsoumian, Hampartsoum B, et al.
Publicado: (2020)

Radiation and Anti-Cancer Vaccines: A Winning Combination
por: Cadena, Alexandra, et al.
Publicado: (2018)

TIGIT Blockade: A Multipronged Approach to Target the HIV Reservoir
por: Holder, Kayla A., et al.
Publicado: (2020)

TIGIT Blockade Exerts Synergistic Effects on Microwave Ablation Against Cancer
por: Chen, Yaping, et al.
Publicado: (2022)

TIGIT blockade repolarizes AML-associated TIGIT(+) M2 macrophages to an M1 phenotype and increases CD47-mediated phagocytosis
por: Brauneck, Franziska, et al.
Publicado: (2022)

NBTXR3 improves the efficacy of immunoradiotherapy combining nonfucosylated anti-CTLA4 in an anti-PD1 resistant lung cancer model
por: Hu, Yun, et al.
Publicado: (2022)

TIGIT blockade enhances functionality of peritoneal NK cells with altered expression of DNAM-1/TIGIT/CD96 checkpoint molecules in ovarian cancer
por: Maas, Ralph Ja, et al.
Publicado: (2020)

Anti-glucocorticoid-induced Tumor Necrosis Factor–Related Protein (GITR) Therapy Overcomes Radiation-Induced Treg Immunosuppression and Drives Abscopal Effects
por: Schoenhals, Jonathan E., et al.
Publicado: (2018)

A Systematic Review and Meta-Analysis on the Significance of TIGIT in Solid Cancers: Dual TIGIT/PD-1 Blockade to Overcome Immune-Resistance in Solid Cancers
por: Hosseinkhani, Negar, et al.
Publicado: (2021)

4-1BB Signaling in Conventional T Cells Drives IL-2 Production That Overcomes CD4(+)CD25(+)FoxP3(+) T Regulatory Cell Suppression
por: Barsoumian, Hampartsoum B., et al.
Publicado: (2016)

TIGIT-CD226-PVR axis: advancing immune checkpoint blockade for cancer immunotherapy
por: Chiang, Eugene Y, et al.
Publicado: (2022)

Nanoparticle-enhanced proton beam immunoradiotherapy drives immune activation and durable tumor rejection
por: Hu, Yun, et al.
Publicado: (2023)

TIGIT in cancer immunotherapy
por: Chauvin, Joe-Marc, et al.
Publicado: (2020)

An engineered oncolytic vaccinia virus encoding a single-chain variable fragment against TIGIT induces effective antitumor immunity and synergizes with PD-1 or LAG-3 blockade
por: Zuo, Shuguang, et al.
Publicado: (2021)

The role of tumor metabolism in modulating T-Cell activity and in optimizing immunotherapy
por: Ganjoo, Shonik, et al.
Publicado: (2023)

Combination TIGIT/PD-1 blockade enhances the efficacy of neoantigen vaccines in a model of pancreatic cancer
por: Peng, Hui, et al.
Publicado: (2022)

Hereditary diffuse gastric cancer therapeutic roadmap: current and novel approaches in a nutshell
por: El Rami, Fadi E., et al.
Publicado: (2020)

Role of Radiation Therapy in Modulation of the Tumor Stroma and Microenvironment
por: Menon, Hari, et al.
Publicado: (2019)

Push and release: TLR9 activation plus STAT3 blockade for systemic antitumor immunity
por: Kortylewski, Marcin, et al.
Publicado: (2014)

Effective Anti-tumor Response by TIGIT Blockade Associated With FcγR Engagement and Myeloid Cell Activation
por: Han, Jin-Hwan, et al.
Publicado: (2020)

TIGIT blockade enhances NK cell activity against autologous HIV‐1‐infected CD4(+) T cells
por: Holder, Kayla A, et al.
Publicado: (2021)

TIGIT blockade enhances tumor response to radiotherapy via a CD103 + dendritic cell-dependent mechanism
por: Zhao, Kaikai, et al.
Publicado: (2022)

Combined Blockade Of PD-1 and TIGIT is not Sufficient to Improve the Function Of CD8+ T-Cells in Chronic Lymphocytic Leukemia
por: Hatefi, Fatemeh, et al.
Publicado: (2022)

Influence of low-dose radiation on abscopal responses in patients receiving high-dose radiation and immunotherapy
por: Menon, Hari, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_u3sb88p3gub0c01p9ikhnr5muq